Infections are a common complication and cause of mortality in transplant and cystic fibrosis patients. Such infections are potentially treatable if appropriate antimicrobials are administered early.

Lung transplant, bone marrow transplant and cystic fibrosis patients bear many similarities to ICU patients with poor outcomes associated with suboptimal antimicrobial dosing.

This population of patients currently have only sparse pharmacokinetic data yet are routinely treated with antimicrobial doses validated in healthy volunteers. A much better characterisation of antimicrobial pharmacokinetics in these patients is required.